Detalhe da pesquisa
1.
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Invest New Drugs
; 42(2): 179-184, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38372949
2.
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Lancet Oncol
; 23(12): 1558-1570, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400106
3.
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Invest New Drugs
; 40(3): 586-595, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35113285
4.
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Invest New Drugs
; 39(6): 1613-1623, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264412
5.
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
Invest New Drugs
; 37(4): 722-730, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30591982
6.
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
Oncologist
; 23(6): 658-e72, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29511132
7.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
; 372(21): 2018-28, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891174
8.
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Invest New Drugs
; 36(4): 629-637, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196957
9.
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
BMC Cancer
; 18(1): 790, 2018 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30081867
10.
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Br J Cancer
; 116(5): 575-583, 2017 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28152546
11.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol
; 17(11): 1497-1508, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27745820
12.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
N Engl J Med
; 369(2): 134-44, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724846
13.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
JAMA
; 315(15): 1600-9, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092830
14.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Lancet
; 384(9948): 1109-17, 2014 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034862
15.
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
Invest New Drugs
; 32(4): 653-60, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24604265
16.
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.
Commun Med (Lond)
; 4(1): 10, 2024 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38218979
17.
Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells.
Cancer Res
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635895
18.
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Clin Ther
; 46(3): 228-238, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423866
19.
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Clin Cancer Res
; 29(12): 2210-2219, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37000164
20.
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
Cancers (Basel)
; 14(20)2022 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291780